The US Food and Drug Administration could decide this week whether to grant accelerated approval to the experimental dementia drug lecanemab.
As featured on
The FDA is expected to decide whether to grant accelerated approval to lecanemab by January 6, Eisai spokesperson Libby Holman confirmed to CNN.
